BEYONTTRA 356 mg film-coated tablets
Sponsors
Bayer Consumer Care AG, Eidos Therapeutics Inc., Medical University Of Vienna
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Transthyretin Amyloidosis
Phase 4
(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.
Not yet recruitingCTIS2025-521831-35-00
Target: 32Updated: 2026-02-09
Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Not yet recruitingCTIS2026-526526-41-01
Target: 10Updated: 2026-07-27
An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Not yet recruitingCTIS2026-526068-19-00
Target: 40Updated: 2026-08-20